The Oncologist, Vol. 8, No. 5, 474487,
October 2003
© 2003 AlphaMed Press
Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation
Carrie A. Thompson,
Tait D. Shanafelt,
Charles L. Loprinzi
Mayo Clinic, Rochester, Minnesota, USA
Correspondence:
Charles L. Loprinzi, M.D., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. Telephone: 507-284-2511; Fax: 507-266-4972; e-mail: cloprinzi{at}mayo.edu
Andropause, or the age-related decline in serum testosterone, has become a popular topic in the medical literature over the past several years. Andropause includes a constellation of symptoms related to lack of androgens, including diminished libido, decreased generalized feeling of well-being, osteoporosis, and a host of other symptoms. The andropause syndrome is very prominent in men undergoing hormonal ablation therapy for prostate cancer. Most significant in this population are the side effects of hot flashes, anemia, gynecomastia, depression, cognitive decline, sarcopenia, a decreased overall quality of life, sexual dysfunction, and osteoporosis with subsequent bone fractures. The concept of andropause in prostate cancer patients is poorly represented in the literature. In this article, we review the current literature on the symptoms, signs, and possible therapies available to men who cannot take replacement testosterone.
Key Words. Prostatic neoplasms • Antineoplastic agents, hormonal • Androgens • Hot flashes • Osteoporosis • Impotence • Quality of life
This article has been cited by other articles:

|
 |

|
 |
 
M. D. Michaelson, S. E. Cotter, P. C. Gargollo, A. L. Zietman, D. M. Dahl, and M. R. Smith
Management of Complications of Prostate Cancer Treatment
CA Cancer J Clin,
July 1, 2008;
58(4):
196 - 213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Engstrom
Hot Flashes in Prostate Cancer: State of the Science
American Journal of Men's Health,
June 1, 2008;
2(2):
122 - 132.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Walczak and M. A. Carducci
Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease
Mayo Clin. Proc.,
February 1, 2007;
82(2):
243 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin
Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
Arch Intern Med,
February 27, 2006;
166(4):
465 - 471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Bhandari, J. Crook, and M. Hussain
Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?
J. Clin. Oncol.,
November 10, 2005;
23(32):
8212 - 8218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nishiyama, F. Ishizaki, T. Anraku, H. Shimura, and K. Takahashi
The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate Cancer
J. Clin. Endocrinol. Metab.,
February 1, 2005;
90(2):
657 - 660.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by AlphaMed Press.
|
|